home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505d.zip
/
M9550869.TXT
< prev
next >
Wrap
Text File
|
1995-03-25
|
2KB
|
35 lines
Document 0869
DOCN M9550869
TI Comparison of metabolism and in vitro antiviral activity of stavudine
versus other 2',3'-dideoxynucleoside analogues.
DT 9505
AU Sommadossi JP; Department of Pharmacology, University of Alabama at
Birmingham; 35294.
SO J Infect Dis. 1995 Mar;171 Suppl 2:S88-92. Unique Identifier : AIDSLINE
MED/95164994
AB 2',3'-dideoxynucleosides are the principal drugs used to treat AIDS and
are the only drugs thus far with demonstrated clinical benefits in
patients with human immunodeficiency virus (HIV) infection. Although
nucleoside analogues are structurally similar and have common mechanisms
of action, each drug has unique molecular, cellular, and clinical
features. For example, 3'-azido-3'-deoxythymidine (zidovudine) and
3'-deoxy-2',3'-didehydrothymidine (stavudine) have similar in vitro
anti-HIV activity but differ in their tendency to produce bone marrow
suppression. Stavudine has been shown to be less myelosuppressive than
zidovudine. With the exception of zidovudine, most of the clinically
evaluated nucleoside analogues, including 2',3'-dideoxyinosine
(didanosine), 2',3'-dideoxycytidine (zalcitabine), and stavudine,
produce dose-dependent peripheral neuropathy. However, recent studies
suggest that neuropathy induced by stavudine may be mediated by
mechanisms different from those of didanosine and zalcitabine.
DE Animal Comparative Study
Dideoxynucleosides/METABOLISM/PHARMACOLOGY/*THERAPEUTIC USE Human HIV
Infections/*DRUG THERAPY/METABOLISM In Vitro
Stavudine/METABOLISM/PHARMACOLOGY/*THERAPEUTIC USE Structure-Activity
Relationship Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S.
JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).